Changes to Opioid Dependence Treatment program: implications for access & transitional arrangements

In the May Federal Budget, it was announced that from 1 July 2023 the more than 50,000 Australians who need treatment for opioid dependency will have funded support to access the treatment they need from their local pharmacy at a cost they can afford, through a $377.3 million investment over 4 years in the Pharmaceutical Benefits Scheme (PBS) Opioid Dependence Treatment program (ODTP). This event, co-hosted with the Australian Injecting and Illicit Drug Users League (AIVL), explores the resultant changes and transitional arrangements, and provides an opportunity to ask any questions arising ahead of implementation. Speakers include:0:00:00 - 0:05:31 - Melanie Walker, CEO, AADC 0:05:32 - 0:08:54 - John Gobeil, CEO, AIVL 0:08:55 - 0:23:49 - David Laffan, Assistant Secretary, Pharmacy Branch, Australian Government Department of Health and Aged Care  0:23:50 - 1:45:18 - Panel speakers include:- David Laffan, Assistant Secretary, Pharmacy Branch, Australian Government Department of Health and Aged Care- Kirsten Buckingham, Director, Alcohol and Other Drugs Branch, Australian Government Department of Health and Aged Care- Rebecca Lang, Deputy Chair, AADC Board and CEO, Queensland Network of Alcohol and Other Drug Agencies (QNADA)- Stephanie Hocking, Director of Clinical Services and Programs, Centre for Alcohol and Other Drugs, NSW Ministry of Health- Chris Gough, President, AIVL and Executive Director, Canberra Alliance for Harm Minimisation & Advocacy (CAHMA)- Ele Morrison, Senior Project Officer, AIVL